

Excorp Medical Explores Chinese Sites

Representatives of Chinese Provinces to Attend Symposium and Grand Opening of Bioscience Zone Facility

Minneapolis, MN - March 28, 2005 - Excorp Medical, Inc. is exploring site locations for commercial operations aimed at introducing its bioartificial liver system in China, where complications of chronic viral hepatitis are a major cause of death. The Company has engaged HS & Associates, Inc., an international consulting firm based in Ham Lake, Minnesota, for this purpose.

Earlier this year requests for proposals were delivered to a number of Chinese economic development organizations that have emphasized biotechnology in their plans.

Economic development officials from several Chinese provinces plan to attend Excorp Medical's April 8th grand opening of its new facility in the Minneapolis University Research Park and a University of Minnesota Symposium on advances in the treatment of liver diseases. Leading experts on liver disease from the University of Minnesota and the University of Pittsburgh will make presentations at this invitation-only event.

Following the Symposium, Excorp Medical will host a reception. The grand opening reception will include a ribbon-cutting by Minneapolis Mayor R.T. Rybak to celebrate the first bioscience company to locate in the city's new bioscience zone.

"We are pleased that the Chinese will be represented at these events and that they have responded with enthusiasm to the opportunity our bioartificial liver technology offers for addressing a major health problem in their country," said Daniel G. Miller, Ph.D., Excorp Medical's President and Chief Executive Officer.

"My colleagues and I have been impressed by the enthusiastic response from the biotechnology and medical communities in China to the bioartificial liver system, which meets a profound national need," said Lili Pan, of HS & Associates.

The Bioartificial Liver System, meant for use in hospitals' intensive care units, is designed to treat patients until their own livers recover or until liver transplants are possible.

Excorp Medical's goal is to be the first firm to introduce a safe, clinically effective bioartificial liver system worldwide. Since its founding in 1995, the Company has successfully completed preclinical trials and the initial portion of its Phase I/II

clinical trials. It plans to continue trials in conjunction with the University of Pittsburgh Medical Center. Liver failure in its various forms affects several million people in the U.S., Europe, and China. Hepatitis B & C, alcohol, cancer, and trauma are major underlying causes of liver failure.

Excorp Medical, Inc.
739 Kasota Avenue
Minneapolis, MN 55414
www.excorp.com

Contact: Joel Papa - joel.papa@excorp.com